September 13, 2007
Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance.
August 14, 2007
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results.
August 7, 2007
Cadence Pharmaceuticals To Host Conference Call And Live Webcast To Discuss Second Quarter 2007 Financial Results.
July 30, 2007
Cadence Pharmaceuticals Announces Agreement With FDA On Increased Enrollment In Phase III Clinical Trial Of Omigard.
June 6, 2007
Cadence Pharmaceuticals To Webcast Corporate Presentation At The Sixth Annual Needham & Company, LLC Biotechnology & Medical Technology Conference.
June 5, 2007
Cadence Pharmaceuticals Names Hazel Aker, J.D. Senior Vice President, General Counsel and Catherine Hardalo, M.D. Vice President, Clinical Development.
May 15, 2007
Cadence Pharmaceuticals To Webcast Corporate Presentation At The Sixth Annual JMP Securities Research Conference.
May 14, 2007
Cadence Pharmaceuticals Reports First Quarter 2007 Financial Results And Development Highlights.
May 8, 2007
Cadence Pharmaceuticals to Host Conference Call and Live Webcast to Discuss First Quarter 2007 Financial Results.
April 30, 2007
Cadence Pharmaceuticals Announces Plan to Increase Number of Patients to be Enrolled in its Phase III Clinical Trial of Omigard™.
April 27, 2007
Cadence Pharmaceuticals to Webcast Corporate Presentation at Two Upcoming Conferences.
March 13, 2007
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Financial Results.
March 6, 2007
Cadence Pharmaceuticals To Webcast Corporate Presentation At The Cowen And Company 27th Annual Health Care Conference.
March 5, 2007
Cadence Pharmaceuticals To Host Conference Call And Live Webcast To Discuss Fourth Quarter And Full Year 2006 Financial Results.
February 15, 2007
Cadence Pharmaceuticals To Webcast Corporate Presentation At Roth Capital Partners 19th Annual OC Conference.
February 8, 2007
Cadence Pharmaceuticals To Webcast Corporate Presentation At BIO CEO & Investor Conference 2007.
January 31, 2007
Cadence Pharmaceuticals To Webcast Corporate Presentation At Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology And Medical Device Conference.
December 18, 2006
Cadence Pharmaceuticals Initiates Pivotal Phase III Clinical Trial Evaluating Intravenous Acetaminophen For Post-Operative Acute Pain.
November 29, 2006
Cadence Pharmaceuticals Reports Third Quarter 2006 Financial Results And Development Highlights.
November 27, 2006
Cadence Pharmaceuticals Webcast Corporate Presentation At Piper Jaffray Health Care Conference.
Cadence Pharmaceuticals To Host Conference Call And Live Webcast To Discuss Third Quarter 2006 Financial Results.
November 13, 2006
Cadence Pharmaceuticals, Inc. Announces Exercise Of Over-Allotment Option By Underwriters.
October 25, 2006
Cadence Pharmaceuticals, Inc. Announces Pricing for Initial Public Offering.
September 20, 2006
Cadence Pharmaceuticals Announces the Appointment of Samuel L. Barker, Ph.D. to the Company’s Board of Directors.
August 14, 2006
Cadence Pharmaceuticals appoints James B. Breitmeyer, M.D., Ph.D. as Chief Medical Officer and names Christopher J. Twomey to its Board of Directors.
July 17, 2006
Cadence Pharmaceuticals, Inc. Files Registration Statement for Proposed Initial Public Offering.
May 8, 2006
Cadence Pharmaceuticals Announces Additions to Senior Management and Board of Directors.
April 19, 2006
Cadence Pharmaceuticals to Present at UBS Global Specialty Pharmaceuticals Conference.
April 3, 2006
Cadence Pharmaceuticals to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference.
March 30, 2006
Cadence Pharmaceuticals Completes Acquisition of IV APAP and Equity Financing.
February 22, 2006
Cadence Pharmaceuticals Announces Acquisition of Second Phase III Product and $60.8 Million Financing.
October 11, 2005
Cadence Pharmaceuticals Announces $25 Million Financing
September 12, 2005
Cadence Pharmaceuticals Appoints James C. Blair, PhD and William R. LaRue to its Board of Directors.
August 30, 2005
Cadence Pharmaceuticals Initiates Confirmatory Phase III Trial of CPI-226 for Catheter-Related Infections.
June 27, 2005
Cadence Pharmaceuticals Finalizes Agreement with FDA on Special Protocol Assessment for Confirmatory Phase III Trial of CPI-226 for Catheter-Related Infections.
April 25, 2005
Cadence Pharmaceuticals Appoints Kenneth Heilbrunn, M.D. as Senior Vice President and Chief Medical Officer.
January 7, 2005
Cadence Pharmaceuticals Completes Name Change and Launches Website.
August 3, 2004
Micrologix and Strata Pharmaceuticals Complete License Agreement for MBI-226.
| 
